Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
25
03
2021
accepted:
07
05
2021
revised:
04
05
2021
pubmed:
28
5
2021
medline:
6
10
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non-relapse mortality rates remain significant. Relapse rates vary between 15 and 25% across retrospective studies and management strategies vary widely, ranging from palliation to adoptive immunotherapy and, in some cases, a second allo-HCT. Moreover, in allo-HCT, there is a higher incidence of poor graft function and graft failure due to splenomegaly and a hostile "pro-inflammatory" marrow niche. The Practice Harmonisation and Guidelines subcommittee of the Chronic Malignancies Working Party (CMWP) of EBMT convened an international panel consisting of transplant haematologists, histopathologists and molecular biologists to propose practical, clinically relevant definitions of graft failure, poor graft function and relapse as well as management strategies following allo-HCT. A systematic approach to molecular monitoring, histopathological assessment and chimerism testing is proposed. These proposed recommendations aim to increase the accuracy and uniformity of reporting and to thereby facilitate the development of more consistent approaches to these challenging issues. In addition, we propose management strategies for these complications.
Identifiants
pubmed: 34040148
doi: 10.1038/s41375-021-01294-2
pii: 10.1038/s41375-021-01294-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2445-2459Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659–68.
Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 2015;29:2126–33.
pubmed: 26293647
doi: 10.1038/leu.2015.233
McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, et al. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Haematol. 2018;182:418–22.
pubmed: 29808926
doi: 10.1111/bjh.15407
McLornan DP, Sirait T, Hernández-Boluda JC, Czerw T, Hayden P, Yakoub-Agha I. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. Curr Res Transl Med. 2020;69:103267.
McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2167–71.
pubmed: 31284069
doi: 10.1016/j.bbmt.2019.06.034
Wolff S. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002;29:545–52.
pubmed: 11979301
doi: 10.1038/sj.bmt.1703389
Valcárcel D, Sureda A. Graft failure. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. p. 307–13. http://link.springer.com/10.1007/978-3-030-02278-5_41 .
Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn B-M, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:537–43.
pubmed: 23222384
doi: 10.1038/bmt.2012.239
Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, et al. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Leukemia. 2021;35:215–24.
pubmed: 32286544
doi: 10.1038/s41375-020-0815-z
Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer International Publishing; 2019. http://link.springer.com/10.1007/978-3-030-02278-5 .
Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, et al. Outcome of allogeneic hematopoietic stem cell transplantation for patients with chronic and advanced phase myelofibrosis. Biol Blood Marrow Transplant. 2016;22:2180–6.
pubmed: 27596130
doi: 10.1016/j.bbmt.2016.08.029
Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1440–3.
pubmed: 24862637
doi: 10.1016/j.bbmt.2014.05.016
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20:382–6.
pubmed: 24321747
doi: 10.1016/j.bbmt.2013.11.034
Alchalby H, Yunus D-R, Zabelina T, Ayuk F, Kröger N. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2016;51:1223–7.
pubmed: 27088376
doi: 10.1038/bmt.2016.98
Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1898–907.
pubmed: 31176790
doi: 10.1016/j.bbmt.2019.05.036
Cuadrado M, Richard M, Szydlo M, Watts M, Patel N, Renshaw H, et al. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica. 2019;105:2639–46.
pmcid: 7604618
doi: 10.3324/haematol.2019.226340
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8.
pubmed: 23838352
pmcid: 4828070
doi: 10.1182/blood-2013-03-488098
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.
pubmed: 16079113
Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32:1189–99.
pubmed: 29472717
pmcid: 5940654
doi: 10.1038/s41375-018-0018-z
Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, et al. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020;10:36.
pubmed: 32157091
pmcid: 7064504
doi: 10.1038/s41408-020-0302-9
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, et al. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2019. https://doi.org/10.3324/haematol.2019.223503 .
Deeg HJ, Salit RB, Monahan T, Schoch G, McFarland C, Scott BL, et al. Early mixed lymphoid donor/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2020;26:2197–203.
pubmed: 32693211
doi: 10.1016/j.bbmt.2020.07.013
pmcid: 8816377
Sale GE, Deeg HJ, Porter BA. Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant. 2006;12:1285–94.
pubmed: 17162210
doi: 10.1016/j.bbmt.2006.07.008
Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, et al. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant. 2015;50:628–36.
pubmed: 25665047
pmcid: 6394215
doi: 10.1038/bmt.2014.323
Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol. 2005;20:879–89.
pubmed: 15944939
Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuk F, et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2014;20:812–5.
pubmed: 24589549
doi: 10.1016/j.bbmt.2014.02.019
Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Beau MM, Bloomfield CD, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–406.
pubmed: 27069254
doi: 10.1182/blood-2016-03-643544
Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis—a consensus-based study. Histopathology. 2016;68:905–15.
pubmed: 26402166
doi: 10.1111/his.12871
Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol. 2013;160:25–34.
pubmed: 23057517
doi: 10.1111/bjh.12075
Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233–42.
pubmed: 30760453
doi: 10.1182/blood-2018-12-890889
Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, et al. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:1095–101.
pubmed: 28389256
doi: 10.1016/j.bbmt.2017.03.034
Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, et al. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. Blood Adv. 2019;3:83–95.
pubmed: 30622146
pmcid: 6325305
doi: 10.1182/bloodadvances.2018026658
Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, et al. Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019;25:1142–51.
pubmed: 30625392
pmcid: 6918823
doi: 10.1016/j.bbmt.2019.01.002
Stevens EA, Jenkins IC, Beppu LW, Zhang Q, Salit R, Loeb KR, et al. Targeted sequencing improves DIPSS-Plus prognostic scoring in myelofibrosis patients undergoing allogeneic transplantation. Biol Blood Marrow Transplant. 2020;26:1371–4.
pubmed: 32194289
doi: 10.1016/j.bbmt.2020.03.007
Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416–30.
pubmed: 30304655
pmcid: 7030948
doi: 10.1056/NEJMoa1716614
Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto J-C, et al. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021;5:1442–51.
pubmed: 33666653
pmcid: 7948260
doi: 10.1182/bloodadvances.2020003444
Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98:722–8.
pubmed: 23300178
pmcid: 3640116
doi: 10.3324/haematol.2012.076901
Shah MV, Patel KP, Luthra R, Shamanna RK, Mehrotra M, Champlin RE, et al. Real time PCR detects relapse of JAK2 V617F myelofibrosis earlier than pyrosequencing after allogeneic transplantation. Biol Blood Marrow Transplant. 2017;23:S298–9.
doi: 10.1016/j.bbmt.2016.12.217
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, et al. Impact of molecular residual disease post allografting in myelofibrosis patients. Bone Marrow Transplant. 2017;52:1526–9.
pubmed: 28714945
doi: 10.1038/bmt.2017.157
Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831–8.
pubmed: 10216077
Byrne JL, Beshti H, Clark D, Ellis I, Haynes AP, Das-Gupta E, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect. Br J Haematol. 2000;108:430–3.
pubmed: 10691877
doi: 10.1046/j.1365-2141.2000.01826.x
Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000;26:697–9.
pubmed: 11035377
doi: 10.1038/sj.bmt.1702568
Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. 2012;159:172–81.
pubmed: 22909192
doi: 10.1111/bjh.12013
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, et al. JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113:1866–8.
pubmed: 19228938
doi: 10.1182/blood-2008-11-190975
Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548–56.
pubmed: 14576063
doi: 10.1182/blood-2003-05-1513
Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105:47–58.
pubmed: 31537691
pmcid: 6939532
doi: 10.3324/haematol.2019.219790
Janson D, Ayuk FA, Wolschke C, Christopeit M, Badbaran A, von Pein U-M, et al. Ruxolitinib for myelofibrosis patients relapsing after allogeneic hematopoietic transplantation. Blood. 2016;128:1948.
doi: 10.1182/blood.V128.22.1948.1948
Nabergoj M, Wang J, Robin M, Kröger N, Angelucci E, Poire X, et al. Outcomes following second allogenic haematopoietic Cell transplantation in patients with myelofibrosis: a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT. Blood. 2019;134:698.
doi: 10.1182/blood-2019-125802
Atagunduz IK, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, et al. Treosulfan-based conditioning regimen for second allograft in patients with myelofibrosis. Cancers. 2020;12:3098.
pmcid: 7690833
doi: 10.3390/cancers12113098
Atagunduz IK, Christopeit M, Ayuk F, Zeck G, Wolschke C, Kröger N. Incidence and outcome of late relapse after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2020;26:2279–84.
pubmed: 32949753
doi: 10.1016/j.bbmt.2020.09.006
Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96:69–79.
pubmed: 33064301
doi: 10.1002/ajh.26020
Petrovic A, Hale G. Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Expert Rev Clin Immunol. 2011;7:515–27.
pubmed: 21787195
doi: 10.1586/eci.11.24
Robin M, Espérou H, De Latour RP, Petropoulou AD, Xhaard A, Ribaud P, et al. correspondence: splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis: correspondence. Br J Haematol. 2010;150:721–4.
pubmed: 20618333
doi: 10.1111/j.1365-2141.2010.08276.x
For the Nordic MPD Study Group, Abelsson J, Merup M, Birgegård G, WeisBjerrum O, Brinch L, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2012;47(Mar):380–6.
De Vos J, Baudoux E, Bay J-O, Calmels B, Cras A, El Cheikh J, et al. Injections de lymphocytes du donneur (DLI): recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull du Cancer. 2019;106:S35–9.
doi: 10.1016/j.bulcan.2018.10.002